Femara(R) (letrozole) FIRST Aromatase Inhibitor to Indicate Overall Survival Benefit Versus tamoxifen When Taken for Five Years After Breast Cancer Surgery
LONDON, December 11 /PRNewswire/ --
- Femara showed reduced risk of death by 13% (P=0.08) versus tamoxifen, despite inclusion of patients who had switched over from tamoxifen to Femara during the…